BioNTech and Genentech have terminated a Phase 2 trial of their personalized mRNA cancer vaccine after safety and efficacy signals failed to match the promise seen in other personalized mRNA approaches. The move comes after Merck and Moderna reported breakout Phase 3 results in a different cancer setting. The decision underscores the challenge of translating individualized neoantigen or tumor-tailored vaccine strategies into consistent benefit when used as standalone therapy. BioNTech said the Phase 2 program was scrapped within weeks of the other companies’ reported successes. The termination is a near-term reminder that personalized mRNA oncology remains scientifically active but operationally high-risk for companies running smaller or less mature efficacy strategies.